Skip to main content
SpringerLink
Log in

Peptide-Based Therapeutic Vaccines for Allergic Diseases: Where Do We Stand?

  • Chapter
Allergy Frontiers: Future Perspectives

Part of the book series: Allergy Frontiers ((ALLERGY,volume 6))

  • 634 Accesses

Abstract

In healthy individuals, the immune system is regulated by a variety of mechanisms, which ensure that balance is maintained between inflammatory and anti-inflammatory responses. The diverse repertoire of antigen-specific lymphocytes harbours the potential for the recognition of self, as well as pathogen-derived epitopes and innocuous environmental antigens. In healthy individuals, lymphocyte reactivity is controlled by the central and peripheral tolerance mechanisms. In allergic and autoimmune conditions, however, inappropriate responses are generated as peripheral regulatory mechanisms fail. Disease-modifying therapeutic strategies aim to re-establish homeostasis between effector and regulatory responses. This has been successfully accomplished through allergen-specific immunotherapy (SIT). Despite the clinical efficacy of this form of therapy, it is associated with frequent and potentially life-threatening adverse events which arise primarily as a result of the allergenicity of the treatment preparation. Several strategies to reduce the allergenicity of this form of treatment, whilst maintaining clinical efficacy, are under development. Peptide immunotherapy is one such approach in which synthetic peptides targeting T cell epitopes of the allergen are administered to allergic subjects. Clinical studies have confirmed findings in experimental models, demonstrating the induction of allergen-specific immunological tolerance. The clinical consequences of tolerance induction are discussed herein.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Floistrup H, Swartz J, Bergstrom A, Alm JS, Scheynius A, van HM, Waser M, Braun-Fahrlander C, Schram-Bijkerk D, Huber M, Zutavern A, von ME, Ublagger E, Riedler J, Michaels KB, Pershagen G. The Parsifal Study Group. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 2006; 117:59–66

    Article  PubMed  Google Scholar 

  2. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567–75

    Article  CAS  PubMed  Google Scholar 

  3. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392–7

    Article  CAS  PubMed  Google Scholar 

  4. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251–6

    Article  PubMed  Google Scholar 

  5. Cookson W. Genetics and genomics of asthma and allergic diseases. Immunol Rev 2002; 190:195–206

    Article  CAS  PubMed  Google Scholar 

  6. von ME. Allergies, infections and the hygiene hypothesis--the epidemiological evidence. Immunobiology 2007; 212:433–9

    Article  Google Scholar 

  7. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911–20

    Article  PubMed  Google Scholar 

  8. Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999; 103:175–83

    Article  CAS  PubMed  Google Scholar 

  9. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med 2004; 199:1679–88

    Article  CAS  PubMed  Google Scholar 

  10. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, Carr VA, Robinson DS. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608–15

    Article  CAS  PubMed  Google Scholar 

  11. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immuno-therapy. Nat Rev Immunol 2006; 6:761–71

    Article  CAS  PubMed  Google Scholar 

  12. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001; 357:752–6

    Article  CAS  PubMed  Google Scholar 

  13. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468–75

    Article  CAS  PubMed  Google Scholar 

  14. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205–14

    Article  CAS  PubMed  Google Scholar 

  15. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52:472–82

    CAS  Google Scholar 

  16. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356–65

    Article  CAS  PubMed  Google Scholar 

  17. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644–51

    Article  CAS  PubMed  Google Scholar 

  18. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178:2123–30

    Article  CAS  PubMed  Google Scholar 

  19. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007–15

    Article  CAS  PubMed  Google Scholar 

  20. Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ, Durham SR. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002; 105:56–62

    Article  CAS  PubMed  Google Scholar 

  21. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Muller U, Blaser K. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98:1676–83

    Article  CAS  PubMed  Google Scholar 

  22. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255–61

    Article  CAS  PubMed  Google Scholar 

  23. Nasser S, Ying S, Meng Q, Kay AB, Ewan P. Interleukin 10 levels increase in cutaneous biopsies of patients undergoing venom immunotherapy. Eur J Immunol 2001; 31:3704–13

    Article  CAS  PubMed  Google Scholar 

  24. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252–9

    CAS  PubMed  Google Scholar 

  25. Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001; 126:97–101

    Article  CAS  PubMed  Google Scholar 

  26. Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microen-vironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999; 13:603–9

    CAS  PubMed  Google Scholar 

  27. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11:S69–S76

    Article  CAS  PubMed  Google Scholar 

  28. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983; 157:1434–47

    Article  CAS  PubMed  Google Scholar 

  29. Counsell CM, Bond JF, Ohman JL, Greenstein JL, Garman RD. Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat. J Allergy Clin Immunol 1996; 98:884–94

    Article  CAS  PubMed  Google Scholar 

  30. Mark PG, Segal DB, Dallaire ML, Garman RD. Human T and B cell immune responses to Fel d 1 in cat-allergic and non-cat-allergic subjects. Clin Exp Allergy 1996; 26:1316–28

    Article  CAS  PubMed  Google Scholar 

  31. Norman PS, Ohman JL, Jr., Long AA, Creticos PS, Gefter MA, Shaked Z, Wood RA, Eggleston PA, Hafner KB, Rao P, Lichtenstein LM, Jones NH, Nicodemus CF. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623–8

    CAS  PubMed  Google Scholar 

  32. Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sobotka A, Lichtenstein LM, Essayan DM. Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998; 101:506–13

    Article  CAS  PubMed  Google Scholar 

  33. Pene J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF, Yssel H, Bousquet J. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998; 102:571–8

    Article  CAS  PubMed  Google Scholar 

  34. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8:1937–45

    Article  CAS  PubMed  Google Scholar 

  35. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999; 93:222–31

    Article  CAS  PubMed  Google Scholar 

  36. Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001; 167:1734–9

    CAS  PubMed  Google Scholar 

  37. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47–53

    Article  CAS  PubMed  Google Scholar 

  38. Alexander C, Ying S, Kay B, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005; 35:52–8

    Article  CAS  PubMed  Google Scholar 

  39. Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60:1269–74

    Article  CAS  PubMed  Google Scholar 

  40. Smith TR, Alexander C, Kay AB, Larche M, Robinson DS. Cat allergen peptide immuno-therapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study. Allergy 2004; 59:1097–101

    Article  CAS  PubMed  Google Scholar 

  41. Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005; 2:e78

    Article  PubMed  Google Scholar 

  42. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC. Immunological unre-sponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 2004; 20:695–705

    Article  CAS  PubMed  Google Scholar 

  43. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K. Successful immu-notherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:747–54

    Article  CAS  PubMed  Google Scholar 

  44. Texier C, Pouvelle S, Busson M, Herve M, Charron D, Menez A, Maillere B. HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000; 164: 3177–84

    CAS  PubMed  Google Scholar 

  45. Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, Maillere B, Kay AB, Larche M. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36:465–74

    Article  CAS  PubMed  Google Scholar 

  46. Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, Corradin G, Spertini F. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111:854–61

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada

    Hardeep S. Asi (Faculty of Health Sciences) & Mark Larché (Faculty of Health Sciences)

Authors
  1. Hardeep S. Asi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Larché
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, Japan

    Ruby Pawankar

  2. University of Southampton Southampton General Hospital, Tremona Road, Southampton, UK

    Stephen T. Holgate

  3. Children's Mercy Hospitals and Clinics UMKC School of Medicine, 2401 Gillham Road, Kansas City, MO, 64108, USA

    Lanny J. Rosenwasser

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer

About this chapter

Cite this chapter

Asi, H.S., Larché, M. (2010). Peptide-Based Therapeutic Vaccines for Allergic Diseases: Where Do We Stand?. In: Pawankar, R., Holgate, S.T., Rosenwasser, L.J. (eds) Allergy Frontiers: Future Perspectives. Allergy Frontiers, vol 6. Springer, Tokyo. https://doi.org/10.1007/978-4-431-99365-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-99365-0_6

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-99364-3

  • Online ISBN: 978-4-431-99365-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation